



DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017

HOUSTON, June 1, 2017 /PRNewswire/ -- DNAtrix, a biopharmaceutical company developing oncolytic virus immunotherapies for cancer, announced today that it will present favorable safety and efficacy data for its lead adenovirus-based product, DNX-2401 (tasadenoturev), for the treatment of glioblastoma at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

The clinical trial results will be presented by investigator Frederick F. Lang, MD, FACS, FAANS, Director of Clinical Research in the Department of Neurosurgery at The University of Texas MD Anderson Cancer Center. The study showed that DNX-2401 administered intratumorally provided clinical benefit and extended survival for patients with recurrent glioblastoma.

"We are honored that our study for recurrent glioblastoma was selected for an oral presentation at ASCO," said Frank Tufaro, PhD, CEO of DNAtrix. "There are very few treatment options at this stage of disease, and we are excited about the possibility that a single dose of DNX-2401 could provide benefit and has the potential to improve the lives of patients and their families."

Details of the presentation are as follows:

Title: Phase 1b Open-Label Randomized Study of the Oncolytic Adenovirus DNX-2401 Administered with or without Interferon Gamma for Recurrent Glioblastoma

Session: Central Nervous System Tumors

Presenter: Frederick F. Lang, MD, FACS, FAANS

Date: Sunday, June 4, 2017, 8:24 - 8:36 AM CDT

Location: S100a

For more information about DNAtrix clinical studies, visit the website

ClinicalTrials.gov: [NCT02197169](https://clinicaltrials.gov/ct2/show/study/NCT02197169) (DNX-2401 ± interferon gamma) and [NCT02798406](https://clinicaltrials.gov/ct2/show/study/NCT02798406) (DNX-2401 + KEYTRUDA).

About DNX-2401

DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other therapies.

About DNatrix

DNatrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. DNatrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.dnatrix.com.

Contact

DNatrix

Imran Alibhai, Ph.D.

S.V.P. Business Development

ialibhai@dnatrix.com

Source: <http://www.prnewswire.com/news-releases/dnatrix-to-present-results-of-dnx-2401-for-recurrent-glioblastoma-at-asco-2017-300467483.html>

June 1st 2017